For investors seeking strong cash generation, shareholder returns, and long-term demand drivers, the global healthcare industry has long been a top draw for portfolios. Firms in the sector, like our latest Best Dividend Capture Pick, have consistently performed well as the world ages and innovation takes hold.
You can check out the Best Dividend Capture Stocks List to explore all the stocks.
Our pick is one of the largest pharmaceutical firms on the planet, and its edge lies in specialization. Rather than targeting rare diseases or cancer, it focuses on something more mundane: legacy and generic drugs. While not glamorous, these therapies form the backbone of our healthcare system, and doctors still prescribe them widely for pain relief, cardiovascular issues, and depression. It’s a steady, boring business that churns out ample cash flow.
However, don’t let the boring nature of legacy drugs fool you — our pick continues to unlock value and growth.
That growth stems from continued restructuring efforts. Created through a spin-off, our pick spent its early years burdened by debt and mixed prospects. A strong plan combining M&A and new drug development has been working in its favor, with earnings rising and margins expanding.
With those growth trends and its steady OTC/consumer business, our pick remains a strong candidate for dividend capture — a strategy that involves buying a stock before its ex-dividend date and selling after the payout is recovered. With an ex-dividend date of Monday, November 23, and a historical average post-dividend recovery period of 6.7 days, our pick is well positioned for this approach.
For investors seeking a combination of income and capital appreciation, our latest pharmaceutical pick could be a lucrative option.
